{
  "id": "5c83ff91617e120c34000005",
  "type": "summary",
  "question": "What is the mechanism of the drug CRT0066101?",
  "ideal_answer": "Recently developed small molecule PKD inhibitors, CID755673 and CRT0066101, provide potentially important pharmacological approaches to further investigate the effect of PKD in pancreatitis therapy",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/29071385",
    "http://www.ncbi.nlm.nih.gov/pubmed/25852060",
    "http://www.ncbi.nlm.nih.gov/pubmed/29270134",
    "http://www.ncbi.nlm.nih.gov/pubmed/20947701",
    "http://www.ncbi.nlm.nih.gov/pubmed/27030010",
    "http://www.ncbi.nlm.nih.gov/pubmed/20442301",
    "http://www.ncbi.nlm.nih.gov/pubmed/26797128",
    "http://www.ncbi.nlm.nih.gov/pubmed/26895471"
  ],
  "snippets": [
    {
      "text": "Recently developed small molecule PKD inhibitors, CID755673 and CRT0066101, provide potentially important pharmacological approaches to further investigate the effect of PKD in pancreatitis therapy",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29270134",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "CRT0066101, an inhibitor of PKD, has antitumor activity in multiple types of carcinomas.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29071385",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Protein kinase D inhibitor CRT0066101 ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29071385",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Inhibitors of PKD (CRT0066101) and G\u03b2\u03b3 (gallein) prevented PAR2-stimulated activation of PKD.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27030010",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Effective Targeting of Estrogen Receptor-Negative Breast Cancers with the Protein Kinase D Inhibitor CRT0066101.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25852060",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "In conclusion, CRT0066101 is a potent and specific PKD family inhibitor.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/20947701",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Our PKD inhibitor discovery program identified CRT0066101 as a specific inhibitor of all PKD isoforms.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/20442301",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "This identifies ER(-) breast cancers as ideal for treatment with the PKD inhibitor CRT0066101.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/25852060",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Recently developed small molecule PKD inhibitors, CID755673 and CRT0066101, provide potentially important pharmacological approaches to further investigate the effect of PKD in pancreatitis therapy.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29270134",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Serine phosphorylation and inhibition of AMPK activity were partially prevented by the broad PKC inhibitor G\u00f66983 and fully prevented by the specific PKD1 inhibitor CRT0066101.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26797128",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "For the present study we hypothesized that a newly developed PKD/PKD1 inhibitor, CRT0066101, would prevent the initial events leading to pancreatitis. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/20947701",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Furthermore, we confirmed that the PRKD1 inhibitor CRT0066101 reduced phosphorylated PKD/PKC\u03bc, leading to suppression of breast cancer stemness through GSK3/\u03b2-catenin signaling. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26895471",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Protein kinase D inhibitor CRT0066101 suppresses bladder cancer growth in vitro and xenografts via blockade of the cell cycle at G2/M. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29071385",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "For the present study we hypothesized that a newly developed PKD/PKD1 inhibitor, CRT0066101, would prevent the initial events leading to pancreatitis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/20947701",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Our results show for the first time that a PKD-specific small-molecule inhibitor CRT0066101 blocks pancreatic cancer growth in vivo and show that PKD is a novel therapeutic target in pancreatic cancer.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/20442301",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Furthermore, we confirmed that the PRKD1 inhibitor CRT0066101 reduced phosphorylated PKD/PKC\u03bc, leading to suppression of breast cancer stemness through GSK3/\u03b2-catenin signaling.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26895471",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": []
}